mdx-1203
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00944905)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD70 antigenINHIBITOR
CD70 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- rachelmycin
Oral
No
Parenteral
No
Topical
No
Also known as
- mdx-1203
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00944905 | Phase 1 | Jul 1, 2009 | Bristol-Myers Squibb |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1